We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Study Explains How Some Cancers Survive Histone Deacetylase Inhibitor Treatment

By LabMedica International staff writers
Posted on 10 Nov 2015
Print article
Cancer researchers believe that they now understand why some types of tumor cells are resistant to an important class of drugs known as histone deacetylase inhibitors.

The histone deacetylase inhibitors (HDACi) are a class of cytostatic agents that inhibit the proliferation of tumor cells in culture and in vivo by inducing cell cycle arrest, differentiation, and/or apoptosis. Histone deacetylase inhibitors exert their anti-tumor effects via the induction of expression changes of oncogenes or tumor suppressors, through modulating the acetylation/deactylation of histones and/or non-histone proteins such as transcription factors.

Vorinostat (suberoylanilide hydroxamic acid), the most widely used HDACi, has been shown to bind to the active site of histone deacetylases and act as a chelator for zinc ions also found in the active site of histone deacetylases. Vorinostat's inhibition of histone deacetylases results in the accumulation of acetylated histones and acetylated proteins, including transcription factors crucial for the expression of genes needed to induce cell differentiation.

HDAC inhibitors can successfully treat certain types of cancer, such as lymphoma, but other types survive this disruption. Investigators at Cancer Research, United Kingdom (London) and the University of Birmingham (United Kingdom) now believe that they have unraveled the reason why HDACi is surprisingly well tolerated by most eukaryotic cells.

They reported in the September 16, 2015, online edition of the journal Epigenetics and Chromatin that they had used high density microarrays to observe dynamic changes in transcript levels that appeared during the first two hours of exposure of cancer cultures to HDACi. There was a consistent response to two different inhibitors at several concentrations. Components of all known lysine acetyltransferase (KAT) complexes were down-regulated, as were genes required for growth and maintenance of the lymphoid phenotype. Up-regulated gene clusters were enriched in regulators of transcription, development, and phenotypic change.

First author Dr. John Halsall, a postdoctoral research fellow at the University of Birmingham, said, "Our work has shown that some cancer cells can survive the gene damage caused by HDAC inhibitor drugs, so we have unveiled a new layer of the cancer cell's defense that we need to target to destroy tumors. If we work out exactly which types of cancer are vulnerable to these drugs we can use them in a smarter way to treat patients more effectively."

Dr. Kat Arney, science information manager at Cancer Research, United Kingdom, said, "Working out how genes are switched on and off in cancer is vital if we are to truly understand and beat the disease. This study could help us tailor how we use HDAC inhibitors so that more patients could benefit from them, and we will continue to work towards finding more effective ways to target cancer's control mechanisms in the future."

Related Links:

Cancer Research, United Kingdom
University of Birmingham


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.